Technology Search
Your search returned '10' results
-
Loxapine inhalation for agitation associated with schizophrenia or bipolar disorder
Agency: NHSC
Name: Loxapine inhalation (Staccato loxapine, AZ-004)
Technology Type: Drug Device
Patient Indications: People with agitation associated with schizophrenia or bipolar disorder.
Entered On: August 24 2010
-
Afatinib for advanced and/or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
Agency: NHSC
Name: Afatinib (BIBW2992)
Technology Type: Drug
Patient Indications: NSCLC with EGFR mutation: locally advanced and/or metastatic – first line.
Entered On: August 18 2010
-
Apixaban for stroke prevention in atrial fibrillation
Agency: NHSC
Name: Apixaban (BMS 562247; BMS 562247-0)
Technology Type: Drug
Patient Indications: Atrial fibrillation (AF) – prevention of stroke in patients with additional risk factor/s for stroke.
Entered On: August 18 2010
-
Axitinib for advanced and/or metastatic renal cell carcinoma – second line.
Agency: NHSC
Name: Axitinib (AG 013736; AG 13736; AG-013736; AG-13,736)
Technology Type: Drug
Patient Indications: Renal cell carcinoma (RCC): advanced and/or metastatic – second line; after failure of one prior systemic therapy including sunitinib, bevacizumab with interferon alpha, temsirolimus, or cytokines (interferon alpha or interleukin-2).
Entered On: August 18 2010
-
Bevacizumab with trastuzumab and docetaxel for metastatic HER2 positive breast cancer
Agency: NHSC
Name: Bevacizumab (Avastin; anti-VEGF monoclonal antibody; R 435; RG435; rhuMAb-VEGF)
Technology Type: Drug
Patient Indications: Breast cancer: metastatic; HER2 positive – first line; in combination with trastuzumab and docetaxel.
Entered On: August 18 2010
-
Oral calcitonin for osteoarthritis (OA) of the knee in men and postmenopausal women – first line
Agency: NHSC
Name: Oral calcitonin (oral salmon calcitonin, salmon calcitonin, SMC-021)
Technology Type: Drug
Patient Indications: Osteoarthritis (OA) of the knee in men and postmenopausal women – first line; monotherapy or in combination with symptom modifying OA drugs.
Entered On: August 16 2010
-
Vorapaxar for acute coronary syndrome
Agency: NHSC
Name: Vorapaxar
Technology Type: Drug
Patient Indications: Acute coronary syndrome: unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI).
Entered On: August 17 2010
-
Erlotinib hydrochloride (Tarceva) for advanced non-small cell lung cancer with activating mutations
Agency: NHSC
Name: Erlotinib hydrochloride (Tarceva, CP-358774, OSI-774, R-1415)
Technology Type: Drug
Patient Indications: • Non-small cell lung cancer (NSCLC): locally advanced and/or metastatic; activating EGFR mutations – first line.
Entered On: August 13 2010
-
OncoVEX GM-CSF for unresectable metastatic melanoma – first and second line treatment
Agency: NHSC
Name: OncoVEX GM-CSF
Technology Type: Drug
Patient Indications: Malignant melanoma: unresectable, locally advanced and/or metastatic – first and second line.
Entered On: August 16 2010
-
Taspoglutide for type 2 diabetes mellitus
Agency: NHSC
Name: Taspoglutide
Technology Type: Drug
Patient Indications: Type 2 diabetes mellitus - in combination with metformin, or metformin and a sulphonylurea or a thiazolidinedione.
Entered On: August 16 2010
